RenovoRx (RNXT) Change in Accured Expenses (2020 - 2026)
RenovoRx (RNXT) posted Change in Accured Expenses of -$391000.0 for Q1 2026, down 423.14% sequentially from $121000.0 in Q4 2025, and up 32.59% YoY from -$294902.5 in Q1 2025.
RenovoRx (RNXT) Change in Accured Expenses (2020 - 2026) Analysis & Trends
RenovoRx has reported Change in Accured Expenses for 7 years, with the latest figure at -$391000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 32.59% year-over-year to -$391000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76000.0 (down 13.43% YoY) and the FY2025 annual result came in at -$265000.0, down 141.67% from the prior year.
- Change in Accured Expenses fell to -$391000.0 in Q1 2026 per RNXT's latest filing, from $121000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $428000.0 in Q3 2023 and troughed at -$641000.0 in Q4 2023.
- A 5-year average of $10647.1 and a median of $103000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1396.3% in 2023, down 16125.0% in 2023.
- Over 5 years, Change in Accured Expenses stood at $4000.0 in 2022, then plunged by 16125.0% to -$641000.0 in 2023, then jumped by 125.59% to $164000.0 in 2024, then slipped by 26.22% to $121000.0 in 2025, then slumped by 423.14% to -$391000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$391000.0, $121000.0, and $103000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | 163,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 163,000.00 |
| Jun 30, 2026 | 163,000.00 |
| Mar 31, 2026 | -391,000.00 |
| Mar 31, 2026 | -391,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 91,000.00 |
| Jun 30, 2025 | 91,000.00 |
| Mar 31, 2025 | -580,000.00 |
| Mar 31, 2025 | -580,000.00 |
| Dec 31, 2024 | 164,000.00 |
| Dec 31, 2024 | 164,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Mar 31, 2024 | 123,000.00 |